446 related articles for article (PubMed ID: 23358177)
21. Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly.
Hu Q; Li W; Hu X; Hu Q; Shen J; Jin X; Zhou J; Tang G; Chu PK
Biomaterials; 2012 Sep; 33(27):6580-91. PubMed ID: 22717365
[TBL] [Abstract][Full Text] [Related]
22. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
23. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
Su L; Wang Y; Xiao M; Lin Y; Yu L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
[TBL] [Abstract][Full Text] [Related]
25. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Wei H; Hellström KE; Hellström I
Gynecol Oncol; 2012 Jun; 125(3):727-33. PubMed ID: 22430613
[TBL] [Abstract][Full Text] [Related]
26. [Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP].
Zhang X; Li N; Wang YH; Huang Y; Xu NZ; Wu LY
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):174-7. PubMed ID: 19615253
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
Ma Z; Wang X; He J; Xia J; Li Y
PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
[TBL] [Abstract][Full Text] [Related]
28. [RNA interference silencing expression of survivin gene and reversing drug resistance of ovarian cancer cell line SKOV3/ADM].
Deng KX; Zhong L; Jiang MX; Wang PL; Chen Y
Zhonghua Fu Chan Ke Za Zhi; 2005 Dec; 40(12):836-9. PubMed ID: 16412331
[TBL] [Abstract][Full Text] [Related]
29. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
30. Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors.
Zhang Z; Liao H; Chen X; Zheng Y; Liu Y; Tao X; Gu C; Dong L; Duan T; Yang Y; Liu X; Yu Y; Feng Y
Eur J Obstet Gynecol Reprod Biol; 2011 Mar; 155(1):69-74. PubMed ID: 21074309
[TBL] [Abstract][Full Text] [Related]
31. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
33. Effect of shRNA targeting survivin on ovarian cancer.
Xing J; Jia CR; Wang Y; Guo J; Cai Y
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1221-9. PubMed ID: 22426961
[TBL] [Abstract][Full Text] [Related]
34. Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance.
Zhang J; Zhao J; Zhang W; Liu G; Yin D; Li J; Zhang S; Li H
Int J Gynecol Cancer; 2012 Nov; 22(9):1450-6. PubMed ID: 23051955
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.
Li J; Jiang K; Qiu X; Li M; Hao Q; Wei L; Zhang W; Chen B; Xin X
BMB Rep; 2014 Jan; 47(1):33-8. PubMed ID: 24209634
[TBL] [Abstract][Full Text] [Related]
37. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
38. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
[TBL] [Abstract][Full Text] [Related]
39. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]